Analysts set UnitedHealth stock price target

Core Insights - UnitedHealth experienced a significant stock decline on April 17, prompting analysts to revise their price targets downward [1][3] - Despite the downgrades, analysts maintain 'buy' ratings for UnitedHealth stock, indicating potential upside [2] - The downward revisions were primarily due to UnitedHealth's earnings report, which missed revenue and EPS expectations, along with a lowered full-year forecast for 2025 [3] Group 1: Stock Performance - UnitedHealth stock plunged 22.38% in a single day, erasing previous recovery gains [5] - Year-to-date, UnitedHealth shares are down 10.23%, with a 9.86% decline over the past 30 days [6] Group 2: Analyst Revisions - Piper Sandler lowered its price target from $600 to $592, while Barclays reduced its target from $642 to $560 [1] - The new price targets suggest a 30.36% upside from Piper Sandler and a 23.32% upside from Barclays [2] Group 3: Earnings Report Impact - UnitedHealth reported revenue of $109.58 billion, missing the expected $111.60 billion [3] - The company announced an EPS of $7.20, below the anticipated $7.29, and revised its 2025 EPS forecast down to $26-$26.50 from $29.50-$30 [3] - The negative earnings report affected not only UnitedHealth but also other companies in the health sector, such as CVS Health and Humana [4]